Join our Provider Relations team members for the virtual provider collaboration session(s). Register Now
Processing...
Please wait while your form is being submitted
Register for the upcoming 2027 Change Provider Trainings
Join our Provider Relations team members for the virtual provider collaboration session(s). Register Now
Effective Dec. 1, 2025, BCBSND will be updating the preferred products within the following medical drug policies. The updated policies can be found at http://www.gatewaypa/medicalpolicy/52 on Dec. 1, 2025. Members with existing approvals for non-preferred products will be allowed to remain on the non-preferred product until their approval has expired. If a member would like to switch to a preferred product prior to the end of their approval expiration date, please contact the Medical Pharmacy Solutions Team at Prime Therapeutics at 800- 424-1708.
Infliximab | |
Preferred Agents | Non-Preferred Agents |
Avsola (infliximab-axxq) - Q5121 Inflectra (infliximab-dyyb) - Q5103 | Infliximab - J1745 Remicade (infliximab) - J1745 Renflexis (infliximab-abda) - Q5104 |
Rituximab | |
Preferred Agents* | Non-Preferred Agent* |
Riabni (rituximab-arrx) – Q5123 Ruxience (rituximab-pvvr) – Q5119 Truxima (rituximab-abbs) – Q5115 | Rituxan (rituximab) – J9312 |
*Not applicable for metastatic cancer indications | |
Beovu and Susvimo | ||
Preferred Agent | Non-Preferred Agents – Step 1 | |
A bevacizumab product | Ahzantive (aflibercept-mrbb) – Q5150 **Byooviz (ranibizumab-nuna) – Q5124 Enzeevu (aflibercept-abzv) – Q5149 Eylea (aflibercept) – J0178 Eylea HD (aflibercept) – J0177 Opuviz (aflibercept-yszy) – Q5153 Pavblu (aflibercept-ayyh) – Q5147 Lucentis (ranibizumab) – J2778 Vabysmo (faricimab-svoa) – J2777 Yesafili (aflibercept-jbvf) – Q5155 | |
**Not applicable to diabetic macular edema | ||
Denosumab | |
Preferred Agents | Non-Preferred Agents |
Jubbonti/Wyost Stoboclo/Osenvelt | Bomyntra/Conexxence Ospomyv/Xbryk Prolia/Xgeva |